Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lipocine has got four cash grants of approximately $978,000 under the US Government's Qualifying Therapeutic Discovery Project (QTDP) program.
Subscribe to our email newsletter
The grants are related to four of Lipocine’s development programs in hormone replacement therapy, high-risk pregnancy support, oral treatment of progressive glioblastoma multiforme and opioid resistant cough in advanced cancer patients.
Lipocine president and CEO Mahesh Patel said that they are pleased with these awards that will help the company to advance development of critical therapies.
Lipocine is a pharmaceutical company leveraging its proprietary drug delivery technologies to commercialise pharmaceutical products.
It is currently focused on developing oral versions of several hormones for use in men and women’s health.
Lipocine is also developing several respiratory and oncology products for out licensing.